132
Participants
Start Date
June 21, 2016
Primary Completion Date
July 11, 2018
Study Completion Date
July 11, 2018
DNA-HIV-PT123 vaccine
Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
Protein/MF59 vaccine
clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
Placebo
Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
Aurum Tembisa CRS, Johannesburg
Aurum Institute Klerksdorp CRS, Klerksdorp
Isipingo CRS, Westville
National Institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC) Network CRS, Mbeya
Matero Reference Clinic CRS, Lusaka
Collaborators (1)
HIV Vaccine Trials Network
NETWORK
IPPOX Foundation
OTHER
Novartis Vaccines
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH